Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer (OTC: BAYRY) reported final PEACE-3 Phase III results showing XOFIGO (radium-223) plus enzalutamide reduced risk of death by 24% (HR 0.76; 95% CI 0.60–0.96; p=0.0096) and extended median overall survival to 38.2 months versus 32.6 months with enzalutamide alone.
The combination also improved radiological progression-free survival (rPFS 19.4 vs. 16.4 months; HR 0.69; p=0.0009). Grade ≥3 treatment-emergent adverse events occurred in 69% vs. 58% of patients. Results presented at ASCO GU 2026 and published simultaneously in Annals of Oncology.
Summary not available.
Bayer (OTC:BAYRY) launched the Heart to Heart Bistro, an immersive dark dining experience with Celebrity Chef Jeff Mauro for American Heart Month on Feb 2026. The campaign ties to the See Your Risks initiative and invites residents of NY, NJ, CT and PA to enter a sweepstakes by completing a 2-minute Heart Health Risk Assessment at SeeYourRisks.com.
The experience uses blindfolded, three-course dining to highlight unseen cardiovascular risk factors and encourage conversations with healthcare professionals.
Bayer (BAYRY) reported that in the global Phase III OCEANIC-STROKE trial, once-daily oral asundexian 50mg reduced recurrent ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001) versus placebo, with no increase in ISTH major bleeding (1.9% vs. 1.7%; HR 1.10).
OCEANIC-STROKE enrolled 12,327 patients and showed consistent benefit across age, sex, stroke subtype, NIHSS, and antiplatelet strategies; asundexian retains Fast Track designation by FDA and remains investigational.
Bayer (OTC: BAYRY) launched the “Highlights REAL” campaign with former quarterback Tony Romo and his father Ramiro to raise awareness of advanced prostate cancer and treatment management. The campaign encourages patients and caregivers to discuss treatment options, including NUBEQA (darolutamide), with their doctor and directs audiences to HighlightsREAL.com. Tony and Ramiro were compensated and are not NUBEQA patients. The release includes important safety information and directs readers to full prescribing information.
Bayer (OTC:BAYRY) announced an investment of more than $45 million CAD to build a canola innovation centre in Winnipeg, Manitoba to strengthen canola R&D in Canada. The centre will support seed development for canola, camelina and winter canola with work on trait integration, yield trial seed processing and seed quality analysis.
Design begins in 2026 with the facility expected to be operational by the end of 2028. The site will consolidate some breeding and seed generation activities while existing Smartpark and Carman sites maintain early breeding workflows and multi-crop nursery operations.
Bayer (OTC:BAYRY) will present main results and a prespecified subgroup analysis from the global Phase III OCEANIC-STROKE trial of asundexian, an investigational once-daily oral Factor XIa inhibitor, during two late-breaking sessions at the International Stroke Conference 2026 in New Orleans on February 4-6, 2026.
The multicenter, randomized, placebo-controlled, double-blind study enrolled >12,300 patients and, according to Bayer, met its primary efficacy and safety endpoints in November 2025.
Bayer (OTC: BAYRY) and Vanderbilt University Medical Center agreed a strategic five-year collaboration to accelerate discovery and development of therapies from target identification through Investigational New Drug (IND) application.
The partnership initially targets cardiovascular and kidney diseases, and will leverage VUMC’s BioVU DNA and plasma datasets and VUMC clinical/preclinical expertise combined with Bayer’s drug discovery and translational capabilities to enable data-driven insights and speed development of precision medicines.
Bayer (OTC:BAYRY) outlined an accelerated Pharmaceuticals growth strategy at the J.P. Morgan Healthcare Conference focusing on oncology, cardiology, neurology, immunology, women’s health, and molecular imaging.
Key facts: five pivotal approvals in 2025; Phase III OCEANIC-STROKE met primary endpoints for asundexian; finerenone (Kerendia) approved in US and Japan for HF with LVEF ≥40% with other markets under review; Nubeqa has treated over 200,000 patients; FDA granted accelerated approval to Hyrnuo (sevabertinib). Bayer launched CGT, gene therapy and imaging programs and acquired two investigational radiotracers to enter molecular imaging.
Bayer (OTC: BAYRY) partnered with actress Gabrielle Union-Wade on the “Life Doesn’t Stop for a Hot Flash” campaign to raise awareness of treatment options for moderate to severe hot flashes due to menopause. The campaign highlights Lynkuet (elinzanetant) 60 mg, a hormone-free, FDA-approved prescription treatment for moderate to severe hot flashes, approved in October 2025, and will run across digital channels and streaming services encouraging conversations with healthcare providers. Safety information and prescribing guidance, including liver monitoring and pregnancy warnings, are included.